17 results on '"Weisel K"'
Search Results
2. POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS
3. HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
4. CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES
5. 998PD - Management of infusion-related reactions (IRRs) in patients (pts) receiving daratumumab plus standard of care for the treatment of multiple myeloma (MM) in the phase 3 studies CASTOR and POLLUX
6. 906O - Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR
7. Outcomes of Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI) Treated With Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in the Phase 3b STRATUS(TM) Trial (MM-010)
8. Adverse Event (AE) Management With Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in the STRATUS(TM) Trial: A Phase 3b Study Evaluating Safety and Efficacy in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM)
9. Health Resource Utilization with Continuous Lenalidomide Treatment (TX) in Elderly Patients (PTS) with newly diagnosed multiple myeloma (NDMM)
10. Outcome after autologous stem cell transplantation for myeloma in patients beyond 60, 65 and 70 years of age: A retrospective Analysis from the German Registry for Stem Cell Transplantation (DRST)
11. Updated Overall Survival (OS) Analysis of the FIRST Study: Lenalidomide Plus Low-Dose Dexamethasone (Rd) Continuous vs Melphalan, Prednisone, and Thalidomide (MPT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM)
12. A phase I/IIa study of the human CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma
13. Survival Outcomes in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM) in the MM 003 Trial: Impact of Stable Disease (SD) as a Response to Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX)
14. STRATUS(TM) (MM 010): A Single Arm, Phase 3b Study Evaluating Safety and Efficacy of Pomalidomide (POM) + Low Dose Dexamethasone (LoDEX) in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM)
15. The Treatment (Tx) of Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: A Systematic Literature Review and Network Meta-Analysis
16. PRM106 - Development of A Conceptual Model of Multiple Myeloma for Use In Economic Modelling: A Systematic Literature Review to Identify The Evidence Base
17. PRM90 - Development and Validation of A Conceptual Model of Multiple Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.